Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PL3100 vs Naproxen GI Safety in At-Risk Adults
NCT01139190Phase 2Completed
- Sponsor
- PLx Pharma Inc.
- Start
- Jul 2010
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PL-3100 in pain and inflammation (2 arms), sponsored by PLx Pharma Inc. Primary endpoint: Degree of GI Injury at Day 15. Started Jul 2010; status: completed.
02
Drugs
PL-3100
03
Conditions
paininflammation
Beyond the preview
Go deeper on NCT01139190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01139190.